(VIANEWS) – Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) rose by a staggering 12.79% to kr0.34 at 11:22 EST on Wednesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI is dropping 0.28% to kr1,206.43, after five successive sessions in a row of losses. This seems, up until now, a somewhat bearish trend trading session today.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-4.14.
Volume
Today’s last reported volume for BERGENBIO is 1707544 which is 26.98% above its average volume of 1344730.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO’s stock is considered to be overbought (>=80).
More news about BERGENBIO (BGBIO.OL).
